IgG Deficiency
2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Prothya BiosolutionsBelgium - Brussels
1 program1
intravenous immunoglobulinsPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Prothya Biosolutionsintravenous immunoglobulins
Allergy TherapeuticsIV Gamunex 10%
Clinical Trials (2)
Total enrollment: 65 patients across 2 trials
Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
Start: Nov 2007Est. completion: Jul 201455 patients
Phase 4Completed
Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections
Start: Dec 2004Est. completion: Dec 200610 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.